Patents Examined by Matthew P Coughlin
  • Use of dihydroisoquinolinium salts for treating keratin materials, compositions and implementation processes
    Patent number: 11406580
    Abstract: Use of dihydroisoquinolinium salts for treating keratin materials, compositions and implementation processes The present invention relates to the use of one or more dihydroisoquinolinium salts for treating keratin materials, in particular keratin fibres, especially human keratin fibres such as the hair. The invention also relates to a process for treating keratin materials using said salts and optionally in the presence of one or more chemical oxidizing agents. A subject of the invention is also a composition for lightening keratin materials, comprising one or more dihydroisoquinolinium salts as defined below and one or more chemical oxidizing agents.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: August 9, 2022
    Assignee: L'OREAL
    Inventors: Stéphane Sabelle, Aziz Fadli, Alexandra Charrier
  • Use of dihydroisoquinolinium double derivatives for treating keratin materials, compositions and implementation processes
    Patent number: 11406579
    Abstract: The present invention relates to the use of one or more dihydroisoquinolinium double salts for treating keratin materials, in particular keratin fibres, especially human keratin fibres such as the hair. The invention also relates to a process for treating keratin materials using said salts and optionally in the presence of one or more chemical oxidizing agents. A subject of the invention is also a composition for lightening keratin materials, comprising one or more dihydroisoquinolinium double salts as defined below and one or more chemical oxidizing agents. The present invention also relates to one or more particular dihydroisoquinolinium double salts and also to compositions containing them, in particular compositions comprising a physiologically acceptable medium.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: August 9, 2022
    Assignee: L'OREAL
    Inventors: Stéphane Sabelle, Aziz Fadli
  • Method for treating an autoimmune neurological disease and/or neurodegenerative disease and pharmaceutical formulations for a liquid dosage form and a controlled release dosage form
    Patent number: 11400054
    Abstract: A method for treating an autoimmune neurological disease and/or a neurodegenerative disease is provided. The method includes administering an effective amount of at least one compound having Formula (I), Formula (II) or Formula (III), or its geometric isomer, enantiomer or diastereomer to a subject in need thereof: wherein is a single or double bond, X is NCH3 or CH2, Y is null, O or N, Z is O or N, R1 is H, OH, and R2 is null, H, C1-C8 alkyl, —(C?O)-alkyl, —(C?O)-aryl, —(C?O)-alkyl-aryl, —(C?O)-heteroaryl, cycloalkyl or heterocycloalkyl, which optionally substituted by one or more of —OH, —NO2, —NH2, —NR3R4, carbonyl, alkoxyl, alkyl or —OCF3, wherein R3 and R4 independently are H, alkyl, —SO2CH3, —(C?O)—CH3 or —(C?O)—NH2.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: August 2, 2022
    Assignee: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Kuo-Kuei Huang, I-Hong Pan, Shu-Fang Wen, Meng-Nan Lin, I-Huang Lu, Zong-Keng Kuo, Chu-Hsun Lu, Tze-Chung Lee, Ya-Yan Yang, Jia-Horng Liaw, Pei-Hsin Lin
  • O/W type emulsion
    Patent number: 11395798
    Abstract: The present invention provides an O/W type emulsion having a volume median diameter of not more than 100 nm and containing a compound represented by the formula (1) wherein Xa and Xb are each independently X1, X2 or a 1,4-piperazinediyl group; s is 1 or 2, R4 is an alkyl group having 1-6 carbon atoms, na and nb are each independently 0 or 1, R1a, R1b, R2a and R2b are each independently an alkylene group having 1-6 carbon atoms, Ya and Yb are each independently an ester bond, or the like, and R3a and R3b are each independently a liposoluble vitamin residue or the like.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: July 26, 2022
    Assignees: NOF CORPORATION, NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
    Inventors: Kota Tange, Yuta Nakai, Hidetaka Akita, Hiroki Tanaka, Ayaka Watanabe, Naoya Miura, Hideyoshi Harashima
  • Tricyclic P2-ligand containing potent HIV-protease inhibitors against HIV/AIDS
    Patent number: 11390630
    Abstract: Various embodiments relate to a compound of the formula (I) and (II), wherein X, X1, X2, X3, and R1-R4 are defined herein, as well as pharmaceutical compositions comprising compounds of the formula (I) and/or (II) and methods of treating an HIV infection comprising administering a therapeutically effective amount of one or more compounds of formula (I) and/or (II), or a pharmaceutical composition comprising compounds of the formula (I) and/or (II), to a patient in need thereof.
    Type: Grant
    Filed: May 4, 2021
    Date of Patent: July 19, 2022
    Assignee: Purdue Research Foundation
    Inventors: Arun K. Ghosh, Hiroaki Mitsuya, Prasanth Reddy Nyalapatla
  • Antibodies to symmetrically dimethylated arginine analytes and use thereof
    Patent number: 11384158
    Abstract: Disclosed is an antibody which binds to a symmetrically dimethylated arginine analyte that can be used to detect a symmetrically dimethylated arginine analyte in a sample, such as in a homogeneous enzyme immunoassay method.
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: July 12, 2022
    Assignee: ARK Diagnostics, Inc.
    Inventors: Johnny Valdez, Byung Sook Moon, Ki Chung, Yunfei Chen
  • Process for preparing esters of N-acylated amino acids with acid-labile keto protective group functions
    Patent number: 11384061
    Abstract: The present invention relates to a novel process for the esterification of N-acylated amino acids which contain an acid-labile keto protective group under alkaline conditions without using a polar aprotic solvent, in which the N-acylated amino acid with acid-labile keto protective group prepared in situ is esterified using an alkyl halide or a mono- or dialkyl ester of sulfuric acid.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: July 12, 2022
    Assignee: BAYER AKTIENGESELLSCHAFT
    Inventors: Albert Schnatterer, Michael Dockner, Peter Bruechner, Thomas Himmler
  • Transdermal UV-curable hydrogel resin, hydrogel curing the same and cataplasm containing the same
    Patent number: 11382868
    Abstract: The present invention relates to a UV-curable hydrogel resin for transdermal administration, a hydrogel prepared using the UV-curable hydrogel resin, and a cataplasm prepared using the UV-curable hydrogel resin. More particularly, the present invention relates to a hydrogel resin with an optimal composition and composition ratio which allows increase in a water content of a hydrogel applied as a drug layer of a cataplasm, skin irritation mitigation, and crosslinking degree adjustment for adhesion control and is capable of controlling drug releasing property and transdermal absorbability, a hydrogel prepared by UV-hardening the hydrogel resin, and a cataplasm including the hydrogel.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: July 12, 2022
    Assignee: ICURE PHARMACEUTICAL INC.
    Inventors: Young Kweon Choi, Yong Ho Oh, Seong Su Kim, Hwan Ki Ho, Song Mi Han, Myung Jin Kim
  • Drug releasing coatings for medical devices
    Patent number: 11376404
    Abstract: Balloon catheters, methods for preparing balloon catheters, and uses of balloon catheters are disclosed. The balloon catheter includes an elongate member, an expandable balloon, and a coating layer overlying an exterior surface of the expandable balloon. The coating layer includes a total drug load of a hydrophobic therapeutic agent and a combination of additives including a first additive and a second additive. The hydrophobic therapeutic agent is paclitaxel, rapamycin, or paclitaxel and rapamycin. The first additive is a surfactant. The second additive is a chemical compound having one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide, or ester groups.
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: July 5, 2022
    Assignee: Lutonix, Inc.
    Inventor: Lixiao Wang
  • Emulsion concentrates of lipophilic compounds
    Patent number: 11369108
    Abstract: The present invention relates to new, solvent-based emulsifiable concentrates of agrochemical active compounds, a process for the preparation of these formulations and their use for the application of the active compounds contained.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: June 28, 2022
    Assignee: BAYER CROPSCIENCE AKTIENGESELLSCHAFT
    Inventor: Gorka Peris
  • Foaming resin composition, preparation method therefor, and foam using same
    Patent number: 11365304
    Abstract: A foaming resin composition of the present invention contains an aromatic vinyl-based resin and zinc oxide, wherein the size ratio (B/A), in which peak A is a 370 nm to 390 nm region and peak B is a 450 nm to 600 nm region, of zinc oxide is approximately 0.01 to approximately 1 when photoluminescence is measured, and the BET surface area thereof is approximately 1 m2/g to approximately 10 m2/g.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: June 21, 2022
    Assignee: Lotte Chemical Corporation
    Inventors: Ju Sung Kim, You Hyun Kim, Yoen Kyoung Kim, Kang Yeol Park, Seung Yong Bae, Bong Jae Jeong
  • Substituted cyclohexyl compounds as NOP inhibiiors
    Patent number: 11365191
    Abstract: Substituted cyclohexyl chemical entities of Formula (I): wherein Ra, G, and Rb have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by nociceptin activity or dopamine signaling; treating neurological disorders, neurodegenerative diseases, depression, and schizophrenia; enhancing the efficiency of cognitive and motor training; and treating peripheral disorders, including renal, respiratory, gastrointestinal, liver, genitourinary, metabolic, and inflammatory disorders.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: June 21, 2022
    Assignee: Dart NeuroScience, LLC
    Inventors: Jillian Basinger Thompson, Brett C. Bookser, Scott Burley, Pablo Garcia-Reynaga, Andrew Hudson, Marco Peters, Benjamin Pratt, Aaron Thompson, Joe Tran, Lino Valdez
  • Chlorotonil derivatives
    Patent number: 11365201
    Abstract: The present invention relates to novel chlorotonil derivatives of formula (I) and the use thereof for the treatment or prophylaxis of bacterial infections and malaria.
    Type: Grant
    Filed: November 7, 2018
    Date of Patent: June 21, 2022
    Assignee: Helmholtz-Zentrum Für Infektionsforschung GmbH
    Inventors: Antione Abou Fayad, Jennifer Herrmann, Katrin Jungmann-Sahner, Rolf Müller, Kathrin Mohr, Steffen Bernecker, Stephan Hüttel, Rolf Jansen, Emilia Oueis, Anastasia Andreas
  • Eicosanoid derivatives
    Patent number: 11365183
    Abstract: The present invention provides compounds (n-3 PUFA derivatives) of formula (I): that modulate conditions associated with cardiac damage, especially cardiac arrhythmias.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: June 21, 2022
    Assignees: MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN, BOARD OF REGENTS OF UNIVERSITY OF TEXAS SYSTEM
    Inventors: Wolf-Hagen Schunck, Gerd Wallukat, Robert Fischer, Cosima Arnold, Dominik N. Mueller, Narender Puli, John R. Falck
  • Polymer-based antimicrobial compositions and methods of use thereof
    Patent number: 11357718
    Abstract: Provided is a polymer-based antimicrobial composition that is non-toxic, water soluble, and that mitigates the transmission of infectious diseases from surfaces. The composition comprises a cationic polymer, at least one adhesion promoter, optionally organic and/or inorganic particles that are photocatalytically active in visible light, and a carrier, in which the components of the composition are not covalently bound to one another. Also provided is an antimicrobial composition that comprises at least (i) a polyethylenimine-based polymer and a carrier or (ii) an organic and/or inorganic particle that is photocatalytically active in visible light, an adhesion promoter, and a carrier. The antimicrobial compositions can be applied to disinfect a surface and to form residual self-sanitizing films on the surface that are removable.
    Type: Grant
    Filed: September 4, 2018
    Date of Patent: June 14, 2022
    Assignee: eXion labs Inc.
    Inventors: Marion L. Chiattello, Mark Oman
  • Long chain glycolipids useful to avoid perishing or microbial contamination of materials
    Patent number: 11350628
    Abstract: The invention relates to the use of, and methods of use employing, certain glycolipid compounds as defined in detail below and having preservative or antimicrobial properties, novel compounds of the glycolipid class, and related invention embodiments. The compounds have the formula I wherein m is 3 to 5, n is 2 to 5, o is 0 or 1 and p is 3 to 17, with the proviso that the sum m+n+o+p is not less than 14; and R is a carbohydrate moiety bound via one of its carbon atoms to the binding oxygen, and/or a physiologically, especially pharmaceutically or nutraceutically or cosmetically, acceptable salt thereof, or an ester thereof, as such or in the form of a composition, where the compound may be present in open chain form and/or in the form of a lactone (FIG. 1).
    Type: Grant
    Filed: June 8, 2021
    Date of Patent: June 7, 2022
    Assignee: IMD Natural Solutions GmbH
    Inventors: Marc Stadler, Jens Bitzer, Bärbel Köpcke, Kathrin Reinhardt, Jana Moldenhauer
  • Resorbable biomimetic prosthetic ligament
    Patent number: 11351288
    Abstract: An artificial ligament prosthesis which is notable in that it comprises a layer totally or partly consisting of PCL fibres. The ligament prosthesis is a biodegradable and “biointegrable” artificial ligament which makes it possible to take away all the apprehensions and uncertainties due to non-degradable synthetic supports. It is a prosthetic structure inspired by and similar to the native tissue, which is biodegradable while being sterilisable. It can optionally be seeded in order to facilitate the formation of functional tissues with controlled cell and tissue activity, having the required mechanical properties. The prosthesis maybe slowly resorbable in order to be gradually replaced with a functional tissue identical to that of the native ligament.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: June 7, 2022
    Assignee: L.A.R.S.—LABORATOIRE D'APPLICATION ET DE RECHERCHE SCIENTIFIQUE
    Inventors: Bernard Brulez, Véronique Migonney, Roger Guilard
  • Phenyl derivatives as cannabinoid receptor 2 agonists
    Patent number: 11339120
    Abstract: The invention relates to a compound of formula (I) wherein R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: July 15, 2020
    Date of Patent: May 24, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Olivier Gavelle, Uwe Grether, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans, Didier Rombach
  • Inhibitors of lysine gingipain
    Patent number: 11332464
    Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: May 17, 2022
    Assignee: CORTEXYME, INC.
    Inventors: Andrei W. Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
  • Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
    Patent number: 11331325
    Abstract: A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed. Methods of treating a hormone deficiency or effecting male contraception with the inventive formulations are also provided.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: May 17, 2022
    Assignee: Clarus Therapeutics, Inc.
    Inventors: Robert E. Dudley, Panayiotis P. Constantinides